Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

We recently published a list of Jim Cramer Says Trump’s Fed Chair Tussle Is Like “The Godfather” & Discusses These 10 Stocks.

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Last year, the company launched cholesterol-lowering drug Inclisiran in India under brand name Sybrava. Eli Lilly is working ... smoking, diabetes and obesity. While the drugs are still in the ...

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... assessing orforglipron’s effectiveness in treating diabetes, obesity, and sleep apnea.

Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and Zepbound generating billions of dollars in annual sales. The company has ...

Initially planning to bring the drug, to the country in 2026, the company ... for glucagon-like peptide-1 (GLP-1)-based therapies, and follows the recent rollout of Mounjaro by Eli Lilly, a ...